Therapeutic value of visual endoscopic retrograde appendicitis therapy in children with acute suppurative appendicitis
- VernacularTitle:直视内镜下逆行阑尾炎治疗术在儿童急性化脓性阑尾炎中的治疗价值
- Author:
Anding ZHANG
1
;
Na FAN
1
;
Mingzhong WANG
1
;
Lingchao ZENG
1
;
Chunhui WANG
1
;
Yan LIN
1
;
Jiaren ZHOU
1
;
Yaping SONG
1
;
Nini ZHANG
1
;
Haiyan WANG
1
;
Hongwei GUO
1
;
Ying ZHOU
1
;
Baoxi WANG
1
;
Xun JIANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Appendicitis; Child; Retrospective studies
- From: Chinese Journal of Pediatrics 2025;63(7):754-758
- CountryChina
- Language:Chinese
- Abstract: Objective:To investigate the therapeutic value of visual endoscopic retrograde appendicitis therapy (vERAT) in pediatric patients with acute suppurative appendicitis (ASA).Methods:This was a retrospective cohort study. A total of 55 ASA patients who underwent vERAT at the Pediatric Department of the Tangdu Hospital of Air Force Medical University between November 2023 and January 2025 were selected and divided into groups based on the presence or absence of fecaliths: fecalith group and non-fecalith group. The baseline characteristics, initial treatment success rates, treatment costs, hospital stay duration, procedure time, and recurrence rates between two groups were compared. Mann-Whitney U test and χ2 test were used to evaluate group differences. Results:A total of 55 ASA patients were enrolled, including 38 males and 17 females, with the age of 11.2 (9.2, 13.1) years. Based on the presence of fecaliths, patients were divided into two groups: fecalith group (32 cases) and non-fecalith group (23 cases). No statistically significant differences were observed between the two groups in terms of age, gender, duration of abdominal pain, white blood cell count, neutrophil percentage, diameter of appendix, thickness of appendix clinical symptoms or signs (all P>0.05). The initial treatment success rates were 91% (29/32) in fecalith group and 96% (22/23) in non-fecalith group, with no statistically significant difference ( P=0.632). However, significant differences were noted in stent placement ( χ2=5.85, P=0.026) and procedure time ( Z=4.75, P<0.001). The follow-up duration time was 6.0 (2.0, 12.0) and 7.0 (2.0, 8.5) months for the fecalith and non-fecalith groups, respectively, with no significant difference ( Z=0.05, P=0.962). The recurrence rates were 14% (4/29) in fecalith group and 5% (1/22) in non-fecalith group, with no statistically significant difference ( P=0.375). Conclusions:vERAT can safely and effectively treat pediatric ASA, regardless of the presence or absence of fecaliths. It can provide a new treatment option for ASA.
